E-Mail
WHO Benjamin Rome, MD, Instructor of Medicine at Harvard Medical School and researcher in the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital; corresponding author of a paper published in
WHAT When drug manufacturers raise the list price for brand-name prescription drugs, do patients out-of-pocket costs rise too? A new study published in
JAMA Network Open by Dr. Benjamin Rome and colleagues in the Brigham s Division of Pharmacoepidemiology and Pharmacoeconomics finds that more than half of patients may experience increases in out-of-pocket spending when drug prices increase.
Rome and co-authors studied 79 brand-name drugs and found that the list price charged by drug manufacturers increased 16.7 percent, the net price (after manufacturer rebates) by 5.4 percent, and average out-of-pocket costs by 3.5 percent from 2015 to 2017. Some commercially insured patients who
Despite Drug Industry Claims, Higher List Prices Do Mean Higher Out-of-Pocket Costs for Many Patients
Share
Filed to:benjamin rome
copaymentdaraprimdrug pricinghealth medical pharmahealth scienceshealthcare reform in the united statesmartin shkrelimedicaremedication costspharmaceutical industrypharmaceuticals policypharmacypharmacy benefit managementprescription drugturing pharmaceuticalsu s healthcare
A pharmacy technician filling out a prescription of Levoxyl at the Rosemont Pharmacy in Portland, Maine on January 18, 2006 (Photo: Joe Raedle, Getty Images)
To sign up for our daily newsletter covering the latest news, features and reviews, head HERE. For a running feed of all our stories, follow us on Twitter HERE. Or you can bookmark the Gizmodo Australia homepage to visit whenever you need a news fix.
Rising out-of-pocket drug costs linked to increase in brand-name prices
By (0)
Rising out-of-pocket drug costs for consumers are linked with increases in charges for brand-name drugs, a new study has found. File Photo by Billie Jean Shaw/UPI
May 4 (UPI) When drug manufacturers raise prices for brand-name prescription medications, consumers see a corresponding increase in out-of-pocket costs above and beyond their insurance co-pays, an analysis published Tuesday by JAMA Network Open found.
Increasing the list price of a brand-name drug by 17% rose the net price the cost after co-pays, rebates or discounts by more than 5%, the data showed.